 |
인쇄하기
취소
|
Schnell Pharm targets W20 bill. sales
Boosted by its active merger with Genexel-Sein and intensive Research and development strategy, Schnell Pharm has set an ambitious goal of 20 billion won in sales next year.
“We will inject money and energy to develop the company's protein medicines and generic antibodies,'' a Schnell spokesman said.
The strategic medicines to be developed by Schnell include COMP-Ang1, a low-toxic remedy ...
“We will inject money and energy to develop the company's protein medicines and generic antibodies,'' a Schnell spokesman said.
The strategic medicines to be developed by Schnell include COMP-Ang1, a low-toxic remedy ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.